home / stock / cgen / cgen news

CGEN News and Press, Compugen Ltd.

Stock Information
Company Name: Compugen Ltd.
Stock Symbol: CGEN
Market: NASDAQ
Menu
CGEN CGEN Quote CGEN Short CGEN News CGEN Articles CGEN Message Board
Get CGEN Alerts

News, Short Squeeze, Breakout and More Instantly...
CGEN - Compugen Q1 2024 Earnings Preview

2024-05-17 13:38:19 ET More on Compugen Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript Compugen names David Silberman as finance chief Compugen GAAP EPS of $0.11 beats by $0.01, revenue of $33.46M beats by $13.46M Seeking Alpha’s Quant Rating on...
CGEN - Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential PR Newswire HOLON, Israel , May 16, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pion...

CGEN - Compugen names David Silberman as finance chief

2024-05-15 07:43:21 ET More on Compugen Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript Compugen GAAP EPS of $0.11 beats by $0.01, revenue of $33.46M beats by $13.46M Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen ...

CGEN - Compugen Appoints David Silberman as Chief Financial Officer

Compugen Appoints David Silberman as Chief Financial Officer PR Newswire HOLON, Israel , May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, toda...
CGEN - Merck discontinues testing of experimental skin cancer combo therapy

2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...

CGEN - Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 PR Newswire HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discov...

CGEN - Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 PR Newswire HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd...
CGEN - Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 PR Newswire HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pione...

CGEN - Compugen to Participate in Two Upcoming Investor Conferences

Compugen to Participate in Two Upcoming Investor Conferences PR Newswire HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, tod...

CGEN - Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy PR Newswire HOLON, Israel , March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in ...
Next 10